{"id":"W2132365366","doi":"10.1158/1078-0432.ccr-09-2944","title":"Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non–Small Cell Lung Cancer Patients","year":2010,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":96,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Tolerability; Lung cancer; Regimen; Internal medicine; Response Evaluation Criteria in Solid Tumors; Adverse effect; Pharmacokinetics; Oncology; Pharmacology; Gastroenterology; Phases of clinical research; Chemotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001433326,0.001492186,0.002512496,0.000442637,0.0005179696,0.00116681,0.001210619,0.00129638,0.003125692],"category_scores_gemma":[0.001152098,0.0008660796,0.0009764973,0.0004850092,0.001565732,0.001025495,0.0004093643,0.003986287,0.000734374],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001067411,"about_ca_system_score_gemma":0.001821094,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001195713,"about_ca_topic_score_gemma":0.002353504,"domain_scores_codex":[0.9994609,0.0002251978,0.00002664932,0.0001146634,0.00005892309,0.0001135862],"domain_scores_gemma":[0.9988865,0.0001647642,0.0001926074,0.0001254206,0.0000570558,0.0005736231],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6486462,0.1889547,0.007399386,0.000640409,0.0008973243,0.0003301566,0.0005784399,0.002521075,0.06967174,0.0002483667,0.0023434,0.07776886],"study_design_scores_gemma":[0.3644114,0.6197512,0.00956281,0.00001652424,0.0001971199,0.0002116365,0.00006125973,0.00115717,0.003338747,0.00008850236,0.001176925,0.00002674334],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960986,0.0006718882,0.0004401985,0.0001383315,0.00008030322,0.001527634,0.0003633008,0.00006538569,0.0006142306],"genre_scores_gemma":[0.993023,0.0006398769,0.001283949,0.0003365651,0.0001365701,0.00212763,0.001111891,0.00001941597,0.001320918],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003125692,"threshold_uncertainty_score":0.0104565,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09942401494546313,"score_gpt":0.4720793940494459,"score_spread":0.3726553791039827,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}